Penumbra, Inc. (NYSE:PEN) Shares Acquired by Quantinno Capital Management LP

Quantinno Capital Management LP increased its position in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 497.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,031 shares of the company's stock after acquiring an additional 7,519 shares during the quarter. Quantinno Capital Management LP's holdings in Penumbra were worth $2,145,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of PEN. China Universal Asset Management Co. Ltd. acquired a new position in shares of Penumbra in the 4th quarter valued at $573,000. E. Ohman J or Asset Management AB raised its position in Penumbra by 10.4% in the 4th quarter. E. Ohman J or Asset Management AB now owns 21,312 shares of the company's stock valued at $5,061,000 after purchasing an additional 2,000 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Penumbra by 1.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 271,574 shares of the company's stock worth $64,493,000 after acquiring an additional 3,807 shares during the last quarter. Washington Capital Management Inc. acquired a new position in shares of Penumbra during the fourth quarter worth $226,000. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of Penumbra by 39.8% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 299,397 shares of the company's stock worth $71,831,000 after acquiring an additional 85,284 shares in the last quarter. Institutional investors and hedge funds own 88.88% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on PEN. JPMorgan Chase & Co. lifted their price target on shares of Penumbra from $230.00 to $285.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 19th. Wall Street Zen cut Penumbra from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Morgan Stanley upped their target price on Penumbra from $240.00 to $260.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 19th. Wells Fargo & Company increased their price objective on Penumbra from $305.00 to $315.00 and gave the company an "overweight" rating in a report on Thursday, April 24th. Finally, BTIG Research reiterated a "buy" rating on shares of Penumbra in a research report on Thursday, April 24th. Three equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Penumbra presently has a consensus rating of "Moderate Buy" and an average target price of $302.40.

Insiders Place Their Bets

In other news, Director Thomas Wilder sold 360 shares of the business's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $264.58, for a total transaction of $95,248.80. Following the sale, the director now owns 4,533 shares of the company's stock, valued at $1,199,341.14. The trade was a 7.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Lambert Shiu sold 501 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $282.88, for a total value of $141,722.88. Following the completion of the transaction, the chief accounting officer now directly owns 32,969 shares of the company's stock, valued at $9,326,270.72. The trade was a 1.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 176,696 shares of company stock worth $50,207,745. 4.20% of the stock is owned by company insiders.

Penumbra Price Performance

Shares of Penumbra stock traded up $1.97 during trading on Monday, reaching $268.72. The company's stock had a trading volume of 235,921 shares, compared to its average volume of 443,992. The business has a 50 day moving average price of $279.68 and a 200-day moving average price of $265.40. Penumbra, Inc. has a 12-month low of $148.00 and a 12-month high of $310.00. The company has a market capitalization of $10.41 billion, a P/E ratio of 790.35, a price-to-earnings-growth ratio of 2.83 and a beta of 0.53. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02.

Penumbra (NYSE:PEN - Get Free Report) last released its earnings results on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, beating analysts' consensus estimates of $0.66 by $0.17. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The company had revenue of $324.14 million during the quarter, compared to the consensus estimate of $315.72 million. During the same quarter last year, the company earned $0.41 earnings per share. Penumbra's quarterly revenue was up 16.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Penumbra, Inc. will post 3.67 EPS for the current year.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.